White blood cells (leukocytes) have extraordinary healing powers. Made in bone marrow and found in the blood and lymph tissues, these colorless cells are a critical part of the body’s immune system. They are also the foundation of myriad research and development projects by biotech companies, pharmaceutical manufacturers and academic research institutions on the front lines of medical innovation.

The American Red Cross Spring Garden Campus in Philadelphia is a leading producer of lifesaving blood products (called Leukopaks) that provide the raw materials fueling remarkable advances in the world biotechnology arena. They are isolated under clean room conditions to prevent any contamination, and subsequently frozen in liquid nitrogen until needed.“Leukopaks empower the entire pipeline of advanced cell-based medicines, from the laboratory bench to the patient’s bedside,” says Samuel Molina, Executive Director, Therapeutic & Cellular Solutions, Manufacturing Science and Technology Laboratories. “Without them, many of today’s cutting-edge treatments would not be possible.”

Molina explains that Biotech firms use Leukopaks to develop revolutionary cell and gene therapies, such as genetically engineering immune cells to destroy cancer cells. They also provide the raw materials for treatments being tested for aggressive cancers like leukemia and lymphoma. “Our largest customer is focused on these novel therapies,” says Matthew Carver, Senior Director, Therapeutic & Cellular Solutions, Cell and Gene Therapy Solutions.

Pharmaceutical companies use Leukopaks to help empower the body’s immune system to target and better fight diseases. These therapies are being tested for cancer treatment as well as autoimmune disorders and chronic infections. Research groups also use them to develop new vaccines and optimize existing ones.

In regenerative medicine, Leukopaks provide monocytes, a type of white blood cell that attacks invading germs or bacteria. Monocytes can be converted into cells that are important for tissue repair. “Biotech companies are using these special cells to develop therapies that could actually heal damaged tissue or organs, potentially offering solutions to heart disease, diabetes and neurological disorders,” says Carver.

---------------

- Written by Rob Wilder